Cargando…
Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
PARP inhibitors (PARPi) have revolutionized the therapeutic landscape of epithelial ovarian cancer (EOC) treatment with outstanding benefits in regard to progression-free survival, especially in patients either carrying BRCA1/2 mutations or harboring defects in the homologous recombination repair sy...
Autores principales: | Coelho, Ricardo, Tozzi, Alessandra, Disler, Muriel, Lombardo, Flavio, Fedier, André, López, Mónica Núñez, Freuler, Florian, Jacob, Francis, Heinzelmann-Schwarz, Viola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616819/ https://www.ncbi.nlm.nih.gov/pubmed/36307400 http://dx.doi.org/10.1038/s41419-022-05347-x |
Ejemplares similares
-
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022) -
Tumor-Associated Glycans and Their Role in Gynecological Cancers: Accelerating Translational Research by Novel High-Throughput Approaches
por: Pochechueva, Tatiana, et al.
Publicado: (2012) -
Outcome in serous ovarian cancer is not associated with LATS expression
por: Montavon, Céline, et al.
Publicado: (2019) -
ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer
por: Montavon Sartorius, Céline, et al.
Publicado: (2018) -
Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients
por: Pochechueva, Tatiana, et al.
Publicado: (2016)